The Possible Cure For The Followup PSYOP-24 "Pandemic"
Yesterday’s article on the “surging” childhood cases of a mysterious mycoplasma pneumonia…
…concluded that inexpensive repurposed drugs could be the best line of defense in the upcoming “pandemics.”
Today we will review a research study entitled, Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies which showed just how effective and safe Ivermectin is for pneumonia, which closely resembles this latest ‘walking pneumonia’ childhood ‘White Lung’ “outbreak”.
In terms of PSYOP-19 pneumonia, we know that the deadly drug Remdesivir induces renal failure which in turn causes fluids to rise up into the lungs. Those fluids were conveniently misdiagnosed as C-19 “pneumonia” to drive mortality data, especially when combined with intubation, which pressurized said fluids and caused painful mass murder via democidal hospital protocols.
From the aforementioned research study:
These in vitro findings were further supported with the results from a double‐blind, placebo‐controlled, randomized clinical trial study, showing that patients who received ivermectin 400 μg/kg single dose have a lower median viral load at Day 4 (161,000 vs. 493,500 copies/ml) and Day 7 post‐treatment (1018 vs. 23,550 copies/ml). The differences were found, rising from a threefold decrease on the fourth day to about 18‐fold lower on the seventh day when compared with placebo. 49 Second, the pathophysiologic process which underlies severe Covid‐19 involves hyperinflammatory response and accumulation of cytokines, called a cytokine storm. A meta‐analysis study has demonstrated that severe Covid‐19 patients tend to produce higher cytokine levels such as interleukin‐6 (IL‐6), IL‐8, IL‐10 and tumour necrosis factor‐α (TNF‐α), in comparison to non‐severe cases. 50 On the other side, an anti‐inflammatory effect was also demonstrated in ivermectin, both in vivo and in vitro studies. Ivermectin can reduce the IL‐1, IL‐6, TNF‐α production and suppressing lipopolysaccharide‐induced nuclear factor‐kappa B translocation. 51 The suppression of mucus due to hypersecretion in the respiratory tract, the reduction of immune cell recruitment, and a decrease in the production of cytokines and immunoglobulin E/immunoglobulin G1 in bronchoalveolar lavage of experimental mice, were found as a consequence of 2 mg/kg of ivermectin administration. 52 These findings suggest that ivermectin has an anti‐inflammatory effect on the lung tissue, besides at the systemic level, which might help to reduce the severity and prevent mortality from Covid‐19.
It can thus be inferred that Ivermectin will have similar effects on walking pneumonia, or mycoplasma pneumonia.
A bit more context on these mysterious childhood mycoplasma pneumonia “outbreaks” from yesterday’s article:
Patients in the county - which is home to around 200,000 people - have tested positive for mycoplasma pneumonia, a bacterial lung infection for which some antibiotics are useless, adenovirus, a normally benign respiratory infections, and strep.
Because mycoplasma lacks a cell wall around their cell membrane, it makes them naturally resistant to antibiotics that target cell wall synthesis; thus, Ivermectin may be an excellent alternative treatment strategy, whether as a standalone approach, or in conjunction with antibiotics like Doxycycline:
In the treatment of mycoplasmal pneumonia, antimicrobials against M pneumoniae are bacteriostatic, not bactericidal. Tetracycline and erythromycin compounds are very effective. The second-generation tetracyclines (doxycycline) and macrolides are the drugs of choice. 
We also know that Ivermectin can effectively treat diseases such as tuberculosis; for example, a research study entitled, Anthelmintic Avermectins Kill My cobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains posited and concluded:
Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis. Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment.
In summary, this is the first report demonstrating the antimycobacterial activity of avermectins. Their established safety profiles in humans and animals make them potential therapeutic options for treating TB.
The overarching point here is that we have truly safe and exceedingly effective cures for “vaccine” adverse events, VAIDS, (turbo) cancers, prion-based diseases, seasonal flu, RSV, and so on and so forth.
They want you dead.
Do NOT comply.